Pediatric Antiphospholipid Antibodies and Antiphospholipid Syndrome

 

 Buy Article Permissions and Reprints

ABSTRACT

Antiphospholipid syndrome (APS) can occur in children, like adults, with the same diverse spectrum of thrombotic sites but predominately with deep vein thrombosis and stroke. In contrast with adults, however, transient nonthrombogenic antiphospholipid (aPL) antibodies are seen more commonly, usually after childhood infections. In those with “true” aPL antibodies, recurrent thrombotic events seem less frequent than in adults, perhaps reflecting the less prothrombotic hemostatic state of childhood.

Children with thrombotic events in APS present difficult management problems, as there is little evidence-based medicine. The duration and intensity of anticoagulation are unresolved management issues, but a target international normalized ratio of 2 to 3 is used by most. Multicenter randomized controlled trials would provide answers to some of these issues but are difficult to organize due to ethical issues and the rarity of the condition. A pediatric APS registry such as the Ped-APS Register is more easy to organize and can yield informative data.

REFERENCES

• 1 Harris E N, Gharavi A E, Boey M L et al.. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus.  Lancet. 1983;  2 1211-1214
  PubMedGoogle Scholar
• 2 Hughes G RV, Harris A E, Gharavi A E. The anticardiolipin syndrome.  J Rheumatol. 1986;  13 486-489
  PubMedGoogle Scholar
• 3 Miyakis S, Lockshin M D, Atsumi T et al.. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).  J Thromb Haemost. 2006;  4 295-300
  CrossrefPubMedGoogle Scholar
• 4 Wise R C, Todd J K. Spontaneous lower extremity venous thrombosis in children.  Am J Dis Child. 1973;  126 766-769
  PubMedGoogle Scholar
• 5 Andrew M, David M, Adams M et al.. Venous thromboembolic complications (VTE) in children: first analysis of the Canadian Registry of VTE.  Blood. 1994;  83 1251-1257
  CrossrefPubMedGoogle Scholar
• 6 Nowak-Gottl U, Koch H G, Aschka I et al.. Resistance to activated protein C (APCR) in children with venous or arterial thromboembolism.  Br J Haematol. 1996;  92 992-998
  CrossrefPubMedGoogle Scholar
• 7 Broderick J, Talbot G T, Prenger E. Stroke in children within a major metropolitan area: the surprising importance of intracerebral hemorrhage.  J Child Neurol. 1993;  8 250-255
  CrossrefPubMedGoogle Scholar
• 8 Williams L S, Garg B P, Cohen M et al.. Subtypes of ischemic stroke in children and young adults.  Neurology. 1997;  49 1541-1545
  PubMedGoogle Scholar
• 9 Avcin T, Silverman E D. Antiphospholipid antibodies in pediatric systemic lupus erythematosus and the antiphospholipid syndrome.  Lupus. 2007;  16 627-633
  CrossrefPubMedGoogle Scholar
• 10 Galli M, Comfurius P, Maassen C et al.. Anticardiolipin antibodies directed not to cardiolipin but to a plasma protein cofactor.  Lancet. 1990;  335 1544-1547
  CrossrefPubMedGoogle Scholar
• 11 Miyakis S, Lockshin M D, Atsumi T et al.. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).  J Thromb Haemost. 2006;  4 295-306
  CrossrefPubMedGoogle Scholar
• 12 Vaarala O, Palosuo T, Kleemola M, Aho K. Anticardiolipin response in acute infections.  Clin Immunol Immunopathol. 1986;  41 8-15
  CrossrefPubMedGoogle Scholar
• 13 Kurugol Z, Vardar F, Ozkinay F, Kavakli K, Ozkinay C. Lupus anticoagulant and protein S deficiency in otherwise healthy children with acute varicella infection.  Acta Paediatr. 2000;  89 1186-1189
  CrossrefPubMedGoogle Scholar
• 14 Manco-Johnson M J, Nuss R, Key N et al.. Lupus anticoagulant and protein S deficiency in children with post varicella purpura fulminans or thrombosis.  J Pediatr. 1996;  128 319-323
  CrossrefPubMedGoogle Scholar
• 15 Levi M. Measuring activated protein C in plasma to assess its role as a critical modulator of coagulation and inflammation.  J Thromb Haemost. 2003;  1 643-644
  CrossrefPubMedGoogle Scholar
• 16 Rapizzi E, Ruffati A, Tonello M et al.. Correction of age of anticardiolipin antibodies cut-off points.  J Clin Lab Anal. 2000;  14 87-90
  CrossrefPubMedGoogle Scholar
• 17 Caporali R, Ravelli A, De Gennaro F, Neirotti G, Montecucco C, Martini A. Prevalence of anticardiolipin antibodies in juvenile arthritis.  Ann Rheum Dis. 1991;  50 599-601
  CrossrefPubMedGoogle Scholar
• 18 Mavradis A K, Terzoglou C, Filopoulou S, Athanasiadou S, Tzioufas A G. Siamopoulou–Mavridou A . Autoantibodies in Greek juvenile chronic arthritis patients.  Clin Exp Rheumatol. 1991;  9 647-652
  PubMedGoogle Scholar
• 19 Gattorno M, Buoncompagni A, Molinari A C et al.. Antiphospholipid antibodies in paediatric systemic lupus erythematosis, juvenile chronic arthritis and overlap syndromes: SLE patients with both lupus anticoagulant and high-titre anticardiolipin antibodies are at risk for clinical manifestations related to the antiphospholipid syndrome.  Br J Rheumatol. 1995;  34 873-881
  CrossrefPubMedGoogle Scholar
• 20 Kontianes S, Miettinen A, Sepala I, Verkasalo M, Maenpaa J. Antiphospholipid antibodies in children.  Acta Paediatr. 1996;  85 614-615
  CrossrefPubMedGoogle Scholar
• 21 Serra C RB, Rodrigues S H, Silva N P, Szatajnbok F R, Andrade L EC. Clinical significance of anticardiolipin antibodies in juvenile idiopathic arthritis.  Clin Exp Rheumatol. 1999;  17 375-380
  PubMedGoogle Scholar
• 22 Avcin T, Ambrozic A, Kuher H, Kveder T, Rozman B. Anticardiolipin and anti-β2GPL antibodies in sera of 61 apparently healthy children at regular preventive visits.  Rheumatology. 2001;  40 565-573
  CrossrefPubMedGoogle Scholar
• 23 Ambrozic A, Avein T, Ichikawa K et al.. Anti-β2GPI antibodies in children with atopic dematitis.  Int Immunol. 2002;  14 823-830
  CrossrefPubMedGoogle Scholar
• 24 Male C, Lechner K, Eichinger S et al.. Clinical significance of lupus anticoagulants in children.  J Pediatr. 1999;  134 199-205
  PubMedGoogle Scholar
• 25 Gallistl S, Muntean W, Leschnik B, Meyers W. Longer aPPT values in healthy children than in adults: no single cause.  Thromb Res. 1997;  88 355-359
  CrossrefPubMedGoogle Scholar
• 26 Siemens H JG, Gutsche S, Bruckner S, Bucsky P, Katus H A. Antiphospholipid antibodies in children without and in adults with and without thrombophilia.  Thromb Res. 2000;  98 241-247
  CrossrefPubMedGoogle Scholar
• 27 Aguilar Franco C, Lucia Cuesta J. Antiphospholipid antibodies in asymptomatic pediatric patients [in Spanish].  An Esp Pediatr. 2001;  54 444-449
  PubMedGoogle Scholar
• 28 Martinuc-Porobic J, Avein T, Bozic B et al.. Anti-phospholipid antibodies following vaccination with recombinant hepatitis B vaccine.  Clin Exp Immunol. 2005;  142 377-380
  CrossrefPubMedGoogle Scholar
• 29 Ravelli A, Martini A. Antiphospholipid antibody syndrome in pediatric patients.  Rheum Dis Clin North Am. 1997;  23 657-676
  CrossrefPubMedGoogle Scholar
• 30 Tucker L B. Antiphospholipid antibodies and antiphospholipid syndromes in children. In: Khamashta MA Hughes Syndrome, Antiphospholipid Syndrome. London, England; Springer 2000: 155-166
  Google Scholar
• 31 Uysal Z, Dogu F, Kurekci A E et al.. Recurrent arterial thrombosis in a child: primary antiphospholipid antibody syndrome.  Pediatr Hematol Oncol. 2002;  19 59-66
  CrossrefPubMedGoogle Scholar
• 32 Manco-Johnson M J, Nuss R. Lupus anticoagulant in children with thrombosis.  Am J Hematol. 1995;  48 240-243
  CrossrefPubMedGoogle Scholar
• 33 Falcini F, Taccetti G, Ermini M, Trapani S, Matucci Cerinic M. Catastrophic antiphospholipid antibody syndrome in pediatric systemic lupus erythematosus.  J Rheumatol. 1997;  24 389-392
  PubMedGoogle Scholar
• 34 Angelini L, Zibordi F, Zorzi G et al.. Neurological disorders, other than stroke, associated with antiphospholipid antibodies in childhood.  Neuropediatrics. 1996;  27 149-153
  Article in Thieme ConnectPubMedGoogle Scholar
• 35 Angelini L, Granata T, Zibordi F, Binelli S, Zorgi G, Besana C. Partial seizures associated with antiphospholipid antibodies in childhood.  Neuropediatrics. 1998;  29 249-253
  Article in Thieme ConnectPubMedGoogle Scholar
• 36 Tucker L B. Antiphospholipid syndrome in childhood: the great unknown.  Lupus. 1994;  3 367-369
  CrossrefPubMedGoogle Scholar
• 37 Ravelli A, Caporali R, Di Fuccia G, Zonta L, Montecucco C, Martini A. Anticardiolipin antibodies in pediatric systemic lupus erythematosus.  Arch Pediatr Adolesc Med. 1994;  148 398-402
  PubMedGoogle Scholar
• 38 Seaman D E, Londino V, Kwoh C K, Medsger T A, Manzi S. Antiphospholipid antibodies in pediatric systemic lupus erythematosis.  Pediatrics. 1995;  96 1040-1045
  PubMedGoogle Scholar
• 39 Shergy W J, Kredich D W, Pisetsky D S. The relationship of anticardiolipin antibodies to disease manifestations in pediatric systemic lupus erythematosis.  J Rheumatol. 1988;  15 1389-1394
  PubMedGoogle Scholar
• 40 Montes de Oca M A, Babron M C, Bletry O et al.. Thrombosis in systemic lupus erythematosus: a French collaborative study.  Arch Dis Child. 1991;  66 713-717
  CrossrefPubMedGoogle Scholar
• 41 Molta C, Meyer O, Dosquet C et al.. Childhood-onset systemic lupus erythematosis: antiphospholipid antibodies in 37 patients and their first-degree relatives.  Pediatrics. 1993;  92 849-853
  PubMedGoogle Scholar
• 42 Massengill S F, Hedrick C, Ayoub E M, Sleasman J W, Kao K J. Antiphospholipid antibodies in pediatric lupus nephritis.  Am J Kidney Dis. 1997;  29 355-361
  CrossrefPubMedGoogle Scholar
• 43 Berube C, Mitchell L, Silverman E et al.. The relationship of antiphospholipid antibodies to thromboembolic events in pediatric patients with systemic lupus erythematosis: a cross-sectional study.  Pediatr Res. 1998;  44 351-356
  CrossrefPubMedGoogle Scholar
• 44 Gedalia A, Molina J F, Garcia C O, Doggett S, Espinoza L R, Gharavi A E. Anticardiolipin antibodies in childhood rheumatic disorders.  Lupus. 1998;  7 551-553
  CrossrefPubMedGoogle Scholar
• 45 Sugita K, Sato Y, Owada Y, Kurosawa H, Eguchi M. Antiphospholipid antibody syndrome followed by systemic lupus erythematosus in a young male with clinical manifestations since infancy.  Pediatr Int. 2001;  43 563-564
  CrossrefPubMedGoogle Scholar
• 46 Avčin T, Cimaz R, Meroni P L. Recent advances in antiphospholipid antibodies and antiphospholipid syndromes in pediatric populations.  Lupus. 2002;  11 4-10
  CrossrefPubMedGoogle Scholar
• 47 Southwood T R, Roberts-Thomson P J, Ahern M J et al.. Autoantibodies in patients with juvenile chronic arthritis and their immediate family members.  Ann Rheum Dis. 1990;  49 968-972
  CrossrefPubMedGoogle Scholar
• 48 Avein T, Benseler S M, Tyrrell P N, Cucnik S, Silverman E D. Longitudinal follow-up study of antiphospholipid antibodies and associated neuropsychiatric manifestations in 137 children with systemic lupus erythematosus (in press).  Arthritis Rheum. 2008;  59 206-213
  CrossrefPubMedGoogle Scholar
• 49 Levy D M, Massicotte M P, Harvey E, Herbert D, Silverman E D. Thromboembolism in paediatric lupus patients.  Lupus. 2003;  12 741-746
  CrossrefPubMedGoogle Scholar
• 50 Male C, Mitchell L, Julian J et al.. Acquired activated protein C resistance is associated with lupus anticoagulants and thrombotic events in pediatric patients with systemic lupus erythematosus.  Blood. 2001;  97 844-849
  CrossrefPubMedGoogle Scholar
• 51 Male C, Foulon D, Hoogendoorn H et al.. Predictive value of persistent versus transient antiphospholipid antibody subtype for the risk of thrombotic events in pediatric patients with systemic lupus erythemasus.  Blood. 2005;  106 4152-4158
  CrossrefPubMedGoogle Scholar
• 52 Miller D J, Maisch S A, Perez M D, Kearney D L, Feltes T F. Fatal myocardial infarction in an 8-year-old girl with systemic lupus erythematosus, Raynaud's phenomenon, and secondary antiphospholipid syndrome.  J Rheumatol. 1995;  22 768-773
  PubMedGoogle Scholar
• 53 Angelini L, Ravelli A, Caporali R, Rumi V, Nardocci N, Martini A. High prevalence of antiphospholipid antibodies in children with idiopathic cerebral ischemia.  Pediatrics. 1994;  94 500-503
  PubMedGoogle Scholar
• 54 Schöning M, Klein R, Krageloh-Mann I et al.. Antiphospholipid antibodies in cerebrovascular ischemia and stroke in childhood.  Neuropediatrics. 1994;  25 8-14
  Article in Thieme ConnectPubMedGoogle Scholar
• 55 Takanashi J, Sugita K, Miyazato S, Sakao E, Miyamoto H, Niimi H. Antiphospholipid antibody syndrome in childhood strokes.  Pediatr Neurol. 1995;  13 323-326
  CrossrefPubMedGoogle Scholar
• 56 Baca V, Garcia-Ramirez R, Ramirez-Lacayo M, Marquez-Enriquez L, Martinez I, Lavalle C. Cerebral infarction and antiphospholipid syndrome in children.  J Rheumatol. 1996;  23 1428-1431
  PubMedGoogle Scholar
• 57 Kenet G, Sadetzki S, Murad H et al.. Factor V Leiden and antiphospholipid antibodies are significant risk factors for ischemic stroke in children.  Stroke. 2000;  31 1283-1288
  CrossrefPubMedGoogle Scholar
• 58 Pilarska E. The significance of antiphospholipid antibodies in ischemic stroke in children in light of the most current studies [in Polish].  Przegl Lek. 2001;  58 22-24
  PubMedGoogle Scholar
• 59 deVeber G, Andrews M, Adams C for the Canadian Pediatric Ischemic Stroke Study Group et al. Cerebral sinovenous thrombosis in children.  N Engl J Med. 2001;  345 417-423
  CrossrefPubMedGoogle Scholar
• 60 Vlachoyiannopoulos P G, Dimou G, Siamopoulou-Mavridou A. Chorea as a manifestation of the antiphospholipid syndrome in childhood.  Clin Exp Rheumatol. 1991;  9 303-305
  PubMedGoogle Scholar
• 61 Besbas N, Damargue I, Ozen S, Aysun S, Saatci U. Association of antiphospholipid antibodies with systemic lupus erythematosus in a child presenting with chorea: a case report.  Eur J Pediatr. 1994;  153 891-893
  CrossrefPubMedGoogle Scholar
• 62 Okun M S, Jummani R R, Carney P R. Antiphospholipid–associated recurrent chorea and ballism in a child with cerebral palsy.  Pediatr Neurol. 2000;  23 62-63
  CrossrefPubMedGoogle Scholar
• 63 Al-Matar M, Jaimes J, Malleson P. Chorea as the presenting clinical feature of primary antiphospholipid syndrome in childhood.  Neuropediatrics. 2000;  31 107-108
  Article in Thieme ConnectPubMedGoogle Scholar
• 64 Hasegawa M, Yamashita J, Yamashita T, Ikeda K, Fujishima Y, Yamazaki M. Spinal cord infarction associated with primary antiphospholipid syndrome in a young child. Case report.  J Neurosurg. 1993;  79 446-450
  CrossrefPubMedGoogle Scholar
• 65 Besbas N, Anlar B, Apak A, Kansu T. Optic neuropathy in primary antiphospholipid syndrome in childhood.  J Child Neurol. 2001;  16 690-693
  CrossrefPubMedGoogle Scholar
• 66 Rumi V, Angelini L, Scioli V, D'Angelo A, Besana C. Primary antiphospholipid syndrome and neurologic events.  Pediatr Neurol. 1993;  9 473-475
  CrossrefPubMedGoogle Scholar
• 67 Agarwal K S, Puliyel J M, Khanduri U. Sudden onset profound deafness in association with antiphospholipid antibodies in a child with SLE.  Indian Pediatr. 2000;  37 1274-1276
  PubMedGoogle Scholar
• 68 Booth F, Yanofsky R, Ross I B, Lawrence P, Oen K. Primary antiphospholipid syndrome with moyamoya-like vascular changes.  Pediatr Neurosurg. 1999;  31 45-48
  CrossrefPubMedGoogle Scholar
• 69 Harel L, Sandborg C, Lee Tvon Scheven E. Neuropsychiatric manifestations in pediatric systemic lupus erythematosus and association with antiphospholipid antibodies.  J Rheumatol. 2006;  33 1873-1877
  PubMedGoogle Scholar
• 70 Avcin T, Benseler S M, Tyrell P N, Cucnik S, Silverman E D. A follow-up study of antiphospholipid antibodies and associated neurophychiatric manifestations in 137 children with systemic lupus erythematosus.  Arthritis Rheum. 2008;  59 206-213
  CrossrefPubMedGoogle Scholar
• 71 Eriksson K, Peltola J, Keranen T, Haapala A M, Koivikko M. High prevalence of antiphospholipid antibodies in children with epilepsy: a controlled study of 50 cases.  Epilepsy Res. 2001;  46 129-137
  CrossrefPubMedGoogle Scholar
• 72 Purandare A, Godil M A, Prakash D, Parker R, Zerah M, Wilson T A. Spontaneous adrenal hemorrhage associated with transient antiphospholipid antibody in a child.  Clin Pediatr (Phila). 2001;  40 347-350
  CrossrefPubMedGoogle Scholar
• 73 Becton D L, Stine K C. Transient lupus anticoagulants associated with hemorrhage rather than thrombosis: the hemorrhagic lupus anticoagulant syndrome.  J Pediatr. 1997;  130 998-1000
  PubMedGoogle Scholar
• 74 Yacobovich J R, Uziel Y, Friedman Z, Radnay J, Wolach B. Diffuse muscular haemorrhage as presenting sign of juvenile systemic lupus erythematosus and lupus anticoagulant hypoprothrombinaemia syndrome.  Rheumatology. 2001;  40 585-587
  CrossrefPubMedGoogle Scholar
• 75 Boffa M C, Lachassinne E. Infant perinatal thrombosis and antiphospholipid antibodies: a review.  Lupus. 2007;  16 634-641
  CrossrefPubMedGoogle Scholar
• 76 Ohtomo Y, Nagaoka R, Watanabe H, Kaneko K, Ohyama S, Yamashiro Y. Non-lupus nephropathy associated with antiphospholipid antibodies.  Pediatr Nephrol. 2000;  15 136-138
  CrossrefPubMedGoogle Scholar
• 77 Minisola G, Porzio V, Bancheri C, Ceralli F, Carnabuci A, Onetti Muda A. Atypical renal onset and involvement in primary antiphospholipid syndrome in a child.  Clin Exp Rheumatol. 1998;  16 102-104
  PubMedGoogle Scholar
• 78 Monastiri K, Selmi H, Tabarki B, Yacoub M, Mahjoub T, Essoussi A S. Primary antiphospholipid syndrome presenting as complicated Henoch-Schonlein purpura.  Arch Dis Child. 2002;  86 132-133
  CrossrefPubMedGoogle Scholar
• 79 Rongioletti F, Ghio L, Ginevri F et al.. Purpura of the ears: a distinctive vasculopathy with circulating autoantibodies complicating long-term treatment with levamisole in children.  Br J Dermatol. 1999;  140 948-951
  CrossrefPubMedGoogle Scholar
• 80 Monagle P, Michelson A D, Bovill W, Andrews M. Antithrombioic therapy in children.  Chest. 2001;  119 344S-370S
  CrossrefPubMedGoogle Scholar
• 81 Massicotte P, Adams M, Marzinotto V, Brooker L A, Andrew M. Low-molecular-weight heparin in pediatric patients with thrombotic disease: a dose finding study.  J Pediatr. 1996;  128 313-318
  CrossrefPubMedGoogle Scholar
• 82 Burak C R, Bowen M D, Barron T F. The use of enoxaparin in children with acute, nonhemorrhagic ischemic stroke.  Pediatr Neurol. 2003;  29 295-298
  CrossrefPubMedGoogle Scholar
• 83 Dix D, Andrew M, Marzinotto V et al.. The use of low-molecular-weight heparin in pediatric patients: a prospective cohort study.  J Pediatr. 2000;  136 439-445
  CrossrefPubMedGoogle Scholar
• 84 Punzalan R C, Hillery C A, Montgomery R R, Scott J P, Gill J C. Low-molecular-weight heparin in thrombotic disease in children and adolescents.  J Pediatr Hematol Oncol. 2000;  22 137-142
  CrossrefPubMedGoogle Scholar
• 85 Albisetti M, Andrew M. Low molecular weight heparin in children.  Eur J Pediatr. 2002;  161 71-77
  CrossrefPubMedGoogle Scholar
• 86 Erkan D, Lockshin M D. New treatments for antiphospholipid syndrome.  Rheum Dis Clin North Am. 2006;  32 129-148
  CrossrefPubMedGoogle Scholar
• 87 Buck M L. Anticoagulation with warfarin in infants and children.  Ann Pharmacother. 1996;  30 1316-1322
  PubMedGoogle Scholar
• 88 Doyle J J, Koren G, Cheng M Y, Blanchette V S. Anticoagulation with sodium warfarin in children: effect of a loading regimen.  J Pediatr. 1988;  113 1095-1097
  CrossrefPubMedGoogle Scholar
• 89 Crowther M A, Ginsberg J S, Julian J et al.. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome.  N Engl J Med. 2003;  349 1133-1138
  CrossrefPubMedGoogle Scholar
• 90 Finazzi G, Marchioli R, Brancaccio V et al.. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS).  J Thromb Haemost. 2005;  3 848-853
  CrossrefPubMedGoogle Scholar
• 91 Khamashta M A, Hunt B J. Moderate-dose oral anticoagulant therapy in patients with the antiphospholipid syndrome?.  J Thromb Haemost. 2005;  3 844-845
  CrossrefPubMedGoogle Scholar

B. J HuntM.D. F.R.C.P. F.R.C.Path. 

Department of Haematology, St Thomas' Hospital

London SE1 7EH, United Kingdom

Email: Beverley.hunt@gstt.nhs.uk